As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 16 June (Tuesday) to 30 June (Tuesday) 2026.

As a preliminary recommendation, the HTA Council recommends the government financing of norepinephrine (as tartrate) 1 mg/mL in 8 mL ampule (concentrate solution for IV infusion). However, due to the substantial budget impact of financing this drug, the DOH should strongly consider conducting price negotiations to ensure affordability and sustainable access to this treatment.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 30 June 2026 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.